A meta-analysis of 118 observational studies indicates that aspirin, when used at low doses (75 mg or 81 mg) for vascular protection in cancer patients, reduces the risk of cancer mortality by approximately 20%. The analysis focused on common cancers such as colon and breast cancer. While aspirin was associated with an increased risk of gastrointestinal bleeds, it did not elevate the risk of fatal bleeds. The study also included a meta-analysis of 11 randomised clinical trials assessing aspirin-induced gastrointestinal bleeds.
Considering the findings of the meta-analysis on aspirin and cancer, what factors do you think should be carefully weighed when deciding on the use of aspirin for vascular protection in cancer patients?